Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Public ClinicalTrials.gov record NCT00354432. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients receiving hormone therapy for prostate cancer. It is not yet known whether soy protein/isoflavones are more effective than venlafaxine when given together or with a placebo in treating hot flashes. PURPOSE: This randomized phase III trial is studying soy protein/isoflavones and venlafaxine to compare how well they work when given together or with a placebo in treating hot flashes in patients receiving hormone therapy for prostate cancer.
Study identification
- NCT ID
- NCT00354432
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- oral soy protein/isoflavones powder Dietary Supplement
- Venlafaxine Drug
- Placebo Powder Dietary Supplement
- Placebo Pill Drug
Dietary Supplement · Drug
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2007
- Primary completion
- Jul 31, 2010
- Completion
- Jul 31, 2010
- Last update posted
- Sep 27, 2021
2007 – 2010
United States locations
- U.S. sites
- 20
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CCOP - Christiana Care Health Services | Newark | Delaware | 19713 | — |
| MBCCOP - JHS Hospital of Cook County | Chicago | Illinois | 60612 | — |
| CCOP - Central Illinois | Decatur | Illinois | 62526 | — |
| CCOP - Northern Indiana CR Consortium | South Bend | Indiana | 46601 | — |
| CCOP - Cedar Rapids Oncology Project | Cedar Rapids | Iowa | 52403 | — |
| MBCCOP - LSU Health Sciences Center | New Orleans | Louisiana | 70112 | — |
| Feist-Weiller Cancer Center at Louisiana State University Health Sciences | Shreveport | Louisiana | 71130-3932 | — |
| CCOP - Michigan Cancer Research Consortium | Ann Arbor | Michigan | 48106 | — |
| CCOP - Beaumont | Royal Oak | Michigan | 48073-6769 | — |
| CCOP - Cancer Research for the Ozarks | Springfield | Missouri | 65804 | — |
| CCOP - Heartland Research Consortium | St Louis | Missouri | 63131 | — |
| CCOP - St. Louis-Cape Girardeau | St Louis | Missouri | 63141 | — |
| Alamance Cancer Center at Alamance Regional Medical Center | Burlington | North Carolina | 27216 | — |
| Southeastern Medical Oncology Center - Goldsboro | Goldsboro | North Carolina | 27534 | — |
| Caldwell Memorial Hospital | Lenoir | North Carolina | 28645 | — |
| Wake Forest University Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157-1096 | — |
| Wake Forest University CCOP Research Base | Winston-Salem | North Carolina | 27157 | — |
| Cancer Centers of the Carolinas - Easley | Greenville | South Carolina | 29615 | — |
| CCOP - Upstate Carolina | Spartanburg | South Carolina | 29303 | — |
| CCOP - St. Vincent Hospital Cancer Center, Green Bay | Green Bay | Wisconsin | 54301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Prostate Cancer trials
Other public records listing Prostate Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07796490: Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer Not yet recruiting
- NCT07781852: Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer Not yet recruiting
- NCT00977457: Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery Active, not recruiting
- NCT04506567: Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC Active, not recruiting
- NCT07768917: Training on Systemic and Organ Spec. PM in PC Not yet recruiting
- NCT07756593: Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00354432, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2021 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00354432 live on ClinicalTrials.gov.